Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
Middle East and Africa Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)
- Report Code : BMIRE00027679
- Pages : 171
The intravenous immunoglobulin market in the MEA is expected to grow from US$ 497.97 million in 2022 to US$ 711.99 million by 2028. It is estimated to grow at a CAGR of 6.1% from 2022 to 2028.
Rising Prevalence of Immunodeficiency Diseases
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most of the primary immunodeficiencies (PID). The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, around 200,000 ITP cases are recorded across the region annually. Thus, increasing prevalence of immunodeficiency diseases drives the growth of the intravenous immunoglobulin market.
Market Overview
The Middle East & Africa intravenous immunoglobulin market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of the Middle East & Africa. Saudi Arabia was this region’s largest intravenous immunoglobulin market in 2021. The Middle East & Africa intravenous immunoglobulin market is anticipated to grow at a CAGR of 6.1% during the forecast period; this growth can be attributed to the increasing government support for healthcare and the rising awareness regarding IgRT. The increasing prevalence of GBS and infectious diseases drives the intravenous immunoglobulin market in Saudi Arabia. According to the article, “Application of intravenous immunoglobulin (IVIg) to modulate inflammation in critical COVID-19,” published in the National Library of Medicine (NLM) in 2021, administration of IVIg within a specific dosage was extremely beneficial toward reducing mortality and perhaps even the length of hospitalization of patients exhibiting severe COVID-19 symptoms.
MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
MEA Intravenous Immunoglobulin Market Segmentation
The MEA intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.
Based on application, the MEA intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.
Based on distribution channel, the MEA intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.
Based on end user, the MEA intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.
Based on country, the market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of MEA. Saudi Arabia dominated the market in 2022.
ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Intravenous Immunoglobulin Market – By Type
1.3.2 MEA Intravenous Immunoglobulin Market – By Application
1.3.3 MEA Intravenous Immunoglobulin Market – By Distribution Channel
1.3.4 MEA Intravenous Immunoglobulin Market – By End User
1.3.5 MEA Intravenous Immunoglobulin Market – By Country
2. MEA Intravenous Immunoglobulin Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Intravenous Immunoglobulin Market – Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.3 Expert Opinion
5. MEA Intravenous Immunoglobulin Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Immunodeficiency Diseases
5.1.2 Increasing Geriatric Population
5.2 Market Restraints
5.2.1 Adverse Effects of Immunoglobulin Therapy
5.3 Future Trends
5.3.1 Strong Pipeline Candidates for IVIG
5.4 Impact Analysis
6. Intravenous Immunoglobulin Market– MEA Analysis
6.1 MEA Intravenous Immunoglobulin Market Revenue Forecast and Analysis
7. MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028– by Type
7.1 Overview
7.2 MEA Intravenous Immunoglobulin Market, By Type 2022 & 2028 (%)
7.3 IgG
7.3.1 Overview
7.3.2 IgG Revenue and Forecast to 2028 (US$ Million)
7.4 IgM
7.4.1 Overview
7.4.2 IgM – Revenue and Forecast to 2028 (US$ Million)
7.5 IgA
7.5.1 Overview
7.5.2 IgA – Revenue and Forecast to 2028 (US$ Million)
7.6 IgE
7.6.1 Overview
7.6.2 IgE – Revenue and Forecast to 2028 (US$ Million)
7.7 IgD
7.7.1 Overview
7.7.2 IgD – Revenue and Forecast to 2028 (US$ Million)
8. MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Application
8.1 Overview
8.2 MEA Intravenous Immunoglobulin Market, By Application 2022 & 2028 (%)
8.3 Hypogammaglobulinemia
8.3.1 Overview
8.3.2 Hypogammaglobulinemia – Market Revenue and Forecast to 2028 (US$ Million)
8.4 Chronic Inflammatory Demyelinating Polyneuropathy
8.4.1 Overview
8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy – Market Revenue and Forecast to 2028 (US$ Million)
8.5 Immunodeficiency Diseases
8.5.1 Overview
8.5.2 Immunodeficiency Diseases – Market Revenue and Forecast to 2028 (US$ Million)
8.6 Myasthenia Gravis
8.6.1 Overview
8.6.2 Myasthenia Gravis – Market Revenue and Forecast to 2028 (US$ Million)
8.7 Multifocal Motor Neuropathy
8.7.1 Overview
8.7.2 Multifocal Motor Neuropathy – Market Revenue and Forecast to 2028 (US$ Million)
8.8 Idiopathic Thrombocytopenic Purpura
8.8.1 Overview
8.8.2 Idiopathic Thrombocytopenic Purpura – Market Revenue and Forecast to 2028 (US$ Million)
8.9 Inflammatory Myopathies
8.9.1 Overview
8.9.2 Inflammatory Myopathies – Market Revenue and Forecast to 2028 (US$ Million)
8.10 Specific Antibody Deficiency
8.10.1 Overview
8.10.2 Specific Antibody Deficiency – Market Revenue and Forecast to 2028 (US$ Million)
8.11 Guillain-Barre Syndrome
8.11.1 Overview
8.11.2 Guillain-Barre Syndrome – Market Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Others – Market Revenue and Forecast to 2028 (US$ Million)
9. MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Distribution Channel
9.1 Overview
9.2 MEA Intravenous Immunoglobulin Market, By Distribution Channel 2022 & 2028 (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy – Market Revenue and Forecast to 2028 (US$ Million)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy – Market Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others – Market Revenue and Forecast to 2028 (US$ Million)
10. MEA Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by End User
10.1 Overview
10.2 MEA Intravenous Immunoglobulin Market, By End User 2022 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals – Market Revenue And Forecasts To 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics – Market Revenue And Forecasts To 2028 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others – Market Revenue And Forecasts To 2028 (US$ Million)
11. MEA Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 – Country Analysis
11.1 Overview
11.1.1 Middle East & Africa Intravenous Immunoglobulin Market Revenue and Forecast to 2028, by Country (%)
11.1.1.1 Saudi Arabia: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.1 Overview
11.1.1.1.2 Saudi Arabia Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
11.1.1.1.4 Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Application (US$ Million)
11.1.1.1.5 Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
11.1.1.1.6 Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By End User (US$ Million)
11.1.1.2 South Africa: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.1 Overview
11.1.1.2.2 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.3 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
11.1.1.2.4 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Application (US$ Million)
11.1.1.2.5 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Distribution Channel (US$ Million)
11.1.1.2.6 South Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By End User (US$ Million)
11.1.1.3 UAE: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.1 Overview
11.1.1.3.2 UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.3 UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
11.1.1.3.4 UAE: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Application (US$ Million)
11.1.1.3.5 UAE: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Distribution Channel (US$ Million)
11.1.1.3.6 UAE: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By End User (US$ Million)
11.1.1.4 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.4.1 Overview
11.1.1.4.2 Rest of the Middle East and Africa Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.3 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
11.1.1.4.4 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Application (US$ Million)
11.1.1.4.5 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By Distribution Channel (US$ Million)
11.1.1.4.6 Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast To 2028, By End User (US$ Million)
12. MEA Intravenous Immunoglobulin Market–Industry Landscape
12.1 Overview
12.2 Inorganic Growth Strategies
12.2.1 Overview
12.3 Organic Growth Strategies
12.3.1 Overview
13. Company Profiles
13.1 Takeda Pharmaceutical Company Limited
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Grifols, S.A.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bio Products Laboratory Ltd.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Shanghai RAAS
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Octapharma AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Kedrion S.p.A
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CSL Behring (CSL Limited)
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Prothya Biosolutions B.V.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms in Intravenous Immunoglobulin Market
LIST OF TABLES
Table 1. MEA Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
Table 2. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
Table 3. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Application (US$ Million)
Table 4. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
Table 5. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By End User (US$ Million)
Table 6. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
Table 7. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Application (US$ Million)
Table 8. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
Table 9. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By End User (US$ Million)
Table 10. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
Table 11. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Application (US$ Million)
Table 12. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
Table 13. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By End User (US$ Million)
Table 14. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Type (US$ Million)
Table 15. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Application (US$ Million)
Table 16. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By Distribution Channel (US$ Million)
Table 17. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028, By End User (US$ Million)
Table 18. Recent Inorganic Growth Strategies in the Intravenous Immunoglobulin Market
Table 19. Recent Organic Growth Strategies in the Intravenous Immunoglobulin Market
Table 20. Glossary of Terms in Intravenous Immunoglobulin Market
LIST OF FIGURES
Figure 1. MEA Intravenous Immunoglobulin Market Segmentation
Figure 2. MEA Intravenous Immunoglobulin Market Segmentation, By Country
Figure 3. MEA Intravenous Immunoglobulin Market Overview
Figure 4. MEA Intravenous Immunoglobulin Market, by Type
Figure 5. MEA Intravenous Immunoglobulin Market, by Country
Figure 6. Middle East & Africa: PEST Analysis
Figure 7. Impact Analysis
Figure 8. MEA Intravenous Immunoglobulin Market– Revenue Forecast and Analysis – 2020 – 2028
Figure 9. MEA Intravenous Immunoglobulin Market, by Type 2022 & 2028 (%)
Figure 10. MEA IgG Revenue and Forecasts to 2028 (US$ Million)
Figure 11. MEA IgM – Revenue and Forecasts to 2028 (US$ Million)
Figure 12. MEA IgA – Revenue and Forecasts to 2028 (US$ Million)
Figure 13. MEA IgE – Revenue and Forecasts to 2028 (US$ Million)
Figure 14. MEA IgD – Revenue and Forecasts to 2028 (US$ Million)
Figure 15. MEA Intravenous Immunoglobulin Market, by Application 2022 & 2028 (%)
Figure 16. MEA Hypogammaglobulinemia – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. MEA Chronic Inflammatory Demyelinating Polyneuropathy – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. MEA Immunodeficiency Diseases – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. MEA Myasthenia Gravis – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. MEA Multifocal Motor Neuropathy – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. MEA Idiopathic Thrombocytopenic Purpura – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. MEA Inflammatory Myopathies – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. MEA Specific Antibody Deficiency – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. MEA Guillain-Barre Syndrome – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. MEA Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. MEA Intravenous Immunoglobulin Market, by Distribution Channel 2022 & 2028 (%)
Figure 27. MEA Hospital Pharmacy – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. MEA Retail Pharmacy – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. MEA Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. MEA Intravenous Immunoglobulin Market, by End User 2022 & 2028 (%)
Figure 31. MEA Hospitals – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 32. MEA Specialty Clinics – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 33. MEA Others- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 34. Middle East & Africa Intravenous Immunoglobulin Market Revenue Overview, by Country, 2022 (US$ Million)
Figure 35. Middle East & Africa Intravenous Immunoglobulin Market Revenue and Forecast to 2028, by Country (%)
Figure 36. Saudi Arabia: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 37. South Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 38. UAE: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 39. Rest of the Middle East and Africa: Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA intravenous immunoglobulin market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the MEA intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the intravenous immunoglobulin market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
● ADMA Biologics, Inc.
● Bio Products Laboratory Ltd.
● CSL Behring (CSL Limited)
● Grifols, S.A.
● Kedrion S.p.A
● Octapharma AG
● Pfizer Inc.
● Prothya Biosolutions B.V.
● Shanghai RAAS
● Takeda Pharmaceutical Company Limited
At 6.1% CAGR, the MEA Intravenous Immunoglobulin Market is speculated to be worth US$ 711.99 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the MEA intravenous immunoglobulin market was valued at US$ 497.97 million in 2022 and is expected to reach US$ 711.99 million by 2028, registering a CAGR of 6.1% from 2022 to 2028. Strong pipeline candidates for IVIG and rising prevalence of immunodeficiency diseases are the critical factors attributed to the market expansion.
Leading players in the intravenous immunoglobulin market have multiple projects and many biological products in pipelines based on proprietary technology. For instance, Evolve Biologics aims to manufacture and market plasma-derived therapeutics using its proprietary PlasmaCap EBA purification technology. The company is in the process of developing portfolio of product candidates, IVIG, which completed its Phase III clinical trial in February 2021. Similarly, Biotest is a global company that offers plasma protein products and biotherapeutic drugs. The company is developing IgG Next Generation, a newly developed polyvalent immunoglobulin preparation for intravenous administration from human plasma to treat immunodeficiencies and autoimmune diseases. In September 2020, the company completed its phase III trial investigating IgG Next Generation for patients with primary immunodeficiency disease (PID). Thus, strong pipeline candidates for IVIG would become the trend in the intravenous immunoglobulin market in the future.
On the contrary, adverse effects of immunoglobulin therapy hurdles the growth of MEA intravenous immunoglobulin market.
Based on type, the MEA intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment held 29.0% market share in 2022, amassing US$ 144.39 million. It is projected to garner US$ 204.96 million by 2028 to expand at 6.0% CAGR during 2022–2028. Based on application, the MEA intravenous immunoglobulin market is segmented hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment held 21.5% market share in 2022, amassing US$ 107.11 million. It is projected to garner US$ 158.10 million by 2028 to expand at 6.7% CAGR during 2022–2028. Based on distribution channel, the MEA intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held 55.4% market share in 2022, amassing US$ 276.00 million. It is projected to garner US$ 391.63 million by 2028 to expand at 6.0% CAGR during 2022–2028. Based on end user, the MEA intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The beverages segment held 47.4% market share in 2022, amassing US$ 235.86 million. It is projected to garner US$ 332.19 million by 2028 to expand at 5.9% CAGR during 2022–2028. Based on country, the MEA intravenous immunoglobulin market is segmented into South Africa, Saudi Arabia, UAE, and the Rest of MEA. Our regional analysis states that Saudi Arabia captured 44.2% market share in 2022. It was assessed at US$ 220.31 million in 2022 and is likely to hit US$ 311.72 million by 2028, exhibiting a CAGR of 6.0% during the forecast period. Key players dominating the MEA intravenous immunoglobulin market are ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited, among others.
In 2022, BPL and Atlantic Research Group entered into long-term collaboration. This agreement establishes ARG as BPL’s preferred contract research organization (CRO) for conducting clinical research trials and providing supportive services for the company’s global new product development programs. The agreement builds on BPL and ARG’s previous successful collaboration on clinical trial programs. In 2021, Grifols began a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.
Related Reports
- $3,000.00 – $5,000.00
